Rethinking the Labeling and Management of Indolent Cancers

This chapter explores the debate among physicians about renaming low-grade cancers, such as grade group 1 prostate cancer and DCIS, to 'indolent lesions of epithelial origin' (IDLES). It emphasizes the importance of patient awareness and informed decision-making regarding their treatment options.